# LJ-4517

| | |
|---|---|
| **Cat. No.:** | HY-151139 |
| **Molecular Formula:** | $C_{19}H_{21}N_5O_3S$ |
| **Molecular Weight:** | 399.47 |
| **Target:** | Adenosine Receptor |
| **Pathway:** | GPCR/G Protein |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | LJ-4517 is a potent $A_{2A}AR$ antagonist, with a $K_i$ of 18.3 nM. LJ-4517 is potent in displacing the binding of [$^3$H]ZM241385 (HY-19532) at WT $A_{2A}AR$[1]. LJ-4517 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. |
| **$IC_{50}$ & Target** | A2AR<br>18.3 nM (Ki) |
| **In Vitro** | LJ-4517 (10 μM) induces cAMP accumulation[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Shiriaeva A, et al. GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor. J Med Chem. 2022 Aug 17.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA